{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:42:15Z","timestamp":1761766935619,"version":"3.41.2"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>To get better insight into the management of non-metastatic castration-resistant prostate cancer (M0 CRPC), in this meta-analysis and review we aimed to present an updated evaluation of the efficacy and safety of novel hormonal therapies (nHT) for M0 CRPC according to final analyses with mature overall survival (OS) and safety data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed metastasis-free survival (MFS), OS, time to prostate-specific antigen (PSA) progression, second-line therapies data, adverse events (AEs), including all AEs, serious AEs (SAEs), AEs leading to discontinuation of trial regimen, AEs leading to death, fatigue, dizziness, cardiovascular events, and fractures; moreover, we evaluated the impact of PSA doubling time (PSA-DT), Eastern Cooperative Oncology Group (ECOG) score, use of bone-targeted therapy, lymph lodes (LN) status, and prior HT on final OS data. A comparison among the placebo arms of the included trials in terms of survival and safety profiles was assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>According to the pooled analysis with updated and mature OS data, OS was significantly improved with nHT compared to placebo (hazard ratio (HR)= 0.74, 95% confidence interval (CI)= 0.66\u20130.84). nHT significantly improved OS over placebo across all pre-specified subgroups. Subgroup analysis revealed a greater OS benefit in patients with PSA-DT &amp;gt;6 months than \u22646 months (HR= 0.69 versus HR= 0.75), ECOG 0 than 1 (HR= 0.70 versus HR= 0.80), N1 disease than N0 (HR= 0.61 versus HR= 0.78), and in those receiving bone-targeted therapy (HR= 0.65 versus HR= 0.74), and a comparable OS by number of prior HT (HR= 0.75 versus HR= 0.76, for HT= 1 and \u22652); yet, differences between pre-specified subgroups were not significant (all p&amp;gt; 0.05). Overall, the nHT arm was significantly associated with higher rates of AEs, when compared with the placebo arm. The long-term analysis showed a worse safety profile with nHT than the interim analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>According to final analyses, nHT have shown to improve OS over placebo in the setting of high-risk M0 CRPC. The long-term analysis showed a worse safety profile with nHT than the interim analysis, whit distinct profiles among different nHT. The lack of survival data regarding second-line therapies remains a major issue.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.700258","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T06:09:59Z","timestamp":1623132599000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Novel Hormonal Therapies for Non-Metastatic Castration-Resistant Prostate Cancer: An Update From Mature Overall Survival Data"],"prefix":"10.3389","volume":"11","author":[{"given":"Martina","family":"Maggi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Salciccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Del Giudice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Maria","family":"Busetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo G.","family":"Falagario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Carrieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Porreca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Battista","family":"Di Pierro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Fasulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Frantellizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"De Vincentis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ettore","family":"De Berardinis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Sciarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.eururo.2017.08.010","article-title":"Management of Patients With Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference Apccc 2017","volume":"73","author":"Gillessen","year":"2018","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.11.023","article-title":"Role of Hormonal Treatment in Prostate Cancer Patients With Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review","volume":"69","author":"van den Bergh","year":"2016","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJM199707313370502","article-title":"Improved Survival in Patients With Locally Advanced Prostate Cancer Treated With Radiotherapy and Goserelin","volume":"337","author":"Bolla","year":"1997","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2017.1333903","article-title":"Tackling non-Metastatic Castration-Resistant Prostate Cancer: Special Considerations in Treatment","volume":"17","author":"Anantharaman","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"B6","unstructured":"MottetN\n            van den BerghRCN\n          Prostate Cancer: European Association of Urology (EAU) Guidelines2019"},{"key":"B7","article-title":"Prevalence of non-Metastatic Castration-Resistant Prostate Cancer in Europe","volume":"2012","author":"Liede","year":"2012","journal-title":"European Society for Medical Oncology, Vienna Austria September 28-October 2"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.e16052","article-title":"International Prevalence of Nonmetastatic (M0) Castration-Resistant Prostate Cancer (CRPC)","volume":"31","author":"Liede","year":"2013","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.529","article-title":"Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in Men With Nonmetastatic, Castration-Resistant Prostate Cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.08.011","article-title":"Apalutamide and Overall Survival in Prostate Cancer","volume":"79","author":"Smith","year":"2021","journal-title":"Eur Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, Castration-Resistant Prostate Cancer and Survival With Darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring Inconsistency in Meta-Analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02228-2","article-title":"Role of Novel Hormonal Therapies in the Management of non-Metastatic Castration-Resistant Prostate Cancer: A Literature-Based Meta-Analysis of Randomized Trials","volume":"22","author":"Roviello","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2020.02.005","article-title":"A Systematic Review and Network Meta-Analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-Resistant Prostate Cancer","volume":"18","author":"Hird","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.03.022","article-title":"Comparative Efficacy of Apalutamide Darolutamide and Enzalutamide for Treatment of Non-Metastatic Castrate-Resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis","volume":"38","author":"Kumar","year":"2020","journal-title":"Urol Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"Suppl 6S: 345. abstract","DOI":"10.1200\/JCO.2018.36.6_suppl.345","article-title":"Blood-Brain Barrier Penetration of [14C]Darolutamide Compared With [14C]Enzalutamide in Rats Using Whole Body Autoradiography","volume":"36","author":"Zurth","year":"2018","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"12007","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a New-Generation Androgen Receptor Inhibitor Targeting Resistance Mechanisms to Androgen Signaling-Directed Prostate Cancer Therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e13157","DOI":"10.1111\/and.13157","article-title":"Psychological Impact of Different Primary Treatments for Prostate Cancer: A Critical Analysis","volume":"51","author":"Maggi","year":"2019","journal-title":"Andrologia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30456-X","article-title":"Effect of Apalutamide on Health-Related Quality of Life in Patients With non-Metastatic Castration-Resistant Prostate Cancer: An Analysis of the SPARTAN Randomised, Placebo-Controlled, Phase 3 Trial","volume":"19","author":"Saad","year":"2018","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30898-2","article-title":"Patient-Reported Outcomes Following Enzalutamide or Placebo in Men With non-Metastatic, Castration-Resistant Prostate Cancer (PROSPER): A Multicentre, Randomised, Double-Blind, Phase 3 Trial","volume":"20","author":"Tombal","year":"2019","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01157-4","article-title":"Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Chowdhury","year":"2020","journal-title":"Adv Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e15608","DOI":"10.1097\/MD.0000000000015608","article-title":"Androgen Receptor Variant 7 (AR-V7) in Sequencing Therapeutic Agents for Castratrion Resistant Prostate Cancer: A Critical Review","volume":"98","author":"Sciarra","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1050","article-title":"Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men With Nonmetastatic Castration-Resistant Prostate Cancer","volume":"25","author":"Fendler","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.700258\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T06:10:03Z","timestamp":1623132603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.700258\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":28,"alternative-id":["10.3389\/fonc.2021.700258"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.700258","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2021,6,8]]},"article-number":"700258"}}